Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Belozeroff, Vasily; Chertow, Glenn M; Graham, Christopher N; Dehmel, Bastian; Parfrey, Patrick S; Briggs, Andrew H

Belozeroff, Vasily; Chertow, Glenn M; Graham, Christopher N; Dehmel, Bastian; Parfrey, Patrick S; Briggs, Andrew H.

Affiliation

Belozeroff V; Amgen Inc., Thousand Oaks, CA, USA. Electronic address: vasilyb@amgen.com.
Chertow GM; Stanford University School of Medicine, Palo Alto, CA, USA.
Graham CN; RTI Health Solutions, Research Triangle Park, NC, USA.
Dehmel B; Amgen Inc., Thousand Oaks, CA, USA.
Parfrey PS; Memorial University, St. John's, Newfoundland, Canada.
Briggs AH; Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK.

Value Health ; 18(8): 1079-87, 2015 Dec.

Article in En | MEDLINE | ID: mdl-26686794

Subject(s)

Calcimimetic Agents/economics; Calcimimetic Agents/therapeutic use; Cinacalcet/economics; Cinacalcet/therapeutic use; Hyperparathyroidism, Secondary/drug therapy; Adult; Aged; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary/complications; Hyperparathyroidism, Secondary/etiology; Hyperparathyroidism, Secondary/mortality; Kidney Failure, Chronic/complications; Kidney Failure, Chronic/therapy; Male; Markov Chains; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Renal Dialysis; United States

Key words

cinacalcet; cost-effectiveness; dialysis; hyperparathyroidism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Calcimimetic Agents / Cinacalcet / Hyperparathyroidism, Secondary Type of study: Clinical_trials / Etiology_studies / Health_economic_evaluation / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google